Published 13 days ago • loading... • Updated 13 days agoShow Less IconJ&J wins China nod for oral psoriasis pill (JNJ:NYSE) Summary by Seeking AlphaJohnson & Johnson (JNJ) has won China approval for Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.Share menu1 Articles1 ArticlesAllLeftCenterRight1Search IconSort IconSeeking AlphaLean RightFactualityOwnershipJ&J wins China nod for oral psoriasis pill (JNJ:NYSE)Johnson & Johnson (JNJ) has won China approval for Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.13 days ago·Ra'anana, IsraelRead Full ArticleThink freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribeBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsCoverage DetailsTotal News Sources1Leaning Left0Leaning Right1Center0Last Updated13 days agoBias Distribution100% RightBias Distribution Too Big Arrow IconToo Big Arrow IconCaret Up Icon100% of the sources lean Right100% RightR 100%Factuality Info IconTo view factuality data please Upgrade to PremiumOwnership Info IconTo view ownership data please Upgrade to VantageSeeking Alpha broke the news in Ra'anana, Israel 13 days ago on Friday, August 28, 2026.Too Big Arrow IconCaret Down IconSources are mostly out of (0)Similar News TopicsJohnson & Johnson Plus IconChina Plus IconShow AllBlindspot Title And LogoStories disproportionately reported by the Left or the RightSee More BlindspotsSimilar News TopicsJohnson & Johnson Plus IconChina Plus IconShow All